Pushkal Garg Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

Pushkal Garg is CMO & EVP Dev & Med Affairs of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 15,705 shares of ALNY, which is worth approximately $3.85 Million. The most recent transaction as insider was on Dec 12, 2024, when has been sold 1,752 shares (Common Stock) at a price of $251.62 per share, resulting in proceeds of $440,838. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.7K

0.62% 3M change

261.45% 12M change

Total Value Held $3.85 Million

Pushkal Garg Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 12 2024	SELL Open market or private sale	$440,838 $251.62 p/Share	1,752 Reduced 10.04%	15,705 Common Stock
Nov 26 2024	SELL Open market or private sale	$421,088 $250.35 p/Share	1,682 Reduced 8.79%	17,457 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	-	3,434 Added 15.21%	19,139 Common Stock
Oct 08 2024	BUY Grant, award, or other acquisition	-	96 Added 0.61%	15,705 Common Stock
Jun 25 2024	SELL Open market or private sale	$482,470 $229.42 p/Share	2,103 Reduced 11.87%	15,609 Common Stock
Jun 24 2024	BUY Grant, award, or other acquisition	-	4,295 Added 19.52%	17,712 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	4,751 Added 26.15%	13,417 Common Stock
Feb 28 2024	SELL Open market or private sale	$89,744 $156.35 p/Share	574 Reduced 6.21%	8,666 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	-	1,908 Added 17.12%	9,240 Common Stock
Feb 16 2024	SELL Open market or private sale	$193,924 $148.26 p/Share	1,308 Reduced 15.14%	7,332 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	4,295 Added 33.2%	8,640 Common Stock
Aug 07 2023	SELL Open market or private sale	$768,710 $184.52 p/Share	4,166 Reduced 48.95%	4,345 Common Stock
Aug 04 2023	SELL Open market or private sale	$647,033 $186.95 p/Share	3,461 Reduced 28.91%	8,511 Common Stock
Aug 03 2023	BUY Grant, award, or other acquisition	-	7,627 Added 38.92%	11,972 Common Stock
Apr 28 2023	SELL Open market or private sale	$487,440 $198.55 p/Share	2,455 Reduced 36.1%	4,345 Common Stock
Apr 27 2023	SELL Open market or private sale	$358,531 $194.96 p/Share	1,839 Reduced 21.29%	6,800 Common Stock
Apr 26 2023	BUY Grant, award, or other acquisition	-	4,294 Added 33.2%	8,639 Common Stock
Mar 03 2023	SELL Open market or private sale	$3,614,400 $200.0 p/Share	18,072 Reduced 80.62%	4,345 Common Stock
Mar 03 2023	BUY Exercise of conversion of derivative security	$482,250 $96.45 p/Share	5,000 Added 18.24%	22,417 Common Stock
Aug 04 2022	SELL Payment of exercise price or tax liability	$1,036,985 $203.89 p/Share	5,086 Reduced 22.6%	17,417 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	11,311 Added 33.45%	22,503 Common Stock

Also insider at

SQZ

SQZ Biotechnologies Co Healthcare

Director

Pushkal Garg

CMO & EVP Dev & Med Affairs

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Value

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

Operation

Value

Type

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Track Activities on ALNY

Account